A Phase 3 interventional study of Abatacept in Arthritis, Rheumatoid, sponsored by Bristol-Myers Squibb. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 20th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 27th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2008, is one of 22 in phase 3, and was the 24th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept
Subcutaneous injection, 125 mg/mL, once weekly, 48 months
Also known as: Orencia, BMS-188667
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), AEs Leading to Discontinuation, and AEs of Interest (AEIs) at Day 85
An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators. Systemic injection reaction occurring ≤ 24 hours after dosing.
Time frame: Day 1 (Baseline) through Day 85
Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), and AEs Leading to Discontinuation
An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators.
Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Number of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality
LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Hemoglobin (g/dL) \>3 decrease from preRx. Hematocrit (%)\<0.75\*preRx. Erythrocytes (\*10\^6 c/uL) \<0.75\*preRx. Platelet count (\*10\^9 c/L) \<0.67\*LLN or 1.5\*ULN or, if preRx\<LLN, use \<0.5\*preRx and \<100,000 mm\^3. Leukocytes (\*10\^3 c/uL) \<0.75\*LLN or \>1.25\*ULN or, if preRx\<LLN, use \<0.8\*preRx or \>ULN or, if preRx\>ULN, use \>1.2\*preRx or \<LLN. Eosinophils \>0.750\*10\^3 c/uL. Lymphocytes \<0.750\*10\^3 c/uL or \>7.50\*10\^3 c/uL.
Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality
LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (U/L) \>2\*ULN or if preRx\>ULN, use 3\*preRx. Alanine aminotransferase (U/L)\>3\*ULN or if preRx\>ULN, use \>4\*preRx. G-glutamyl transferase (U/L)\>2\*ULN or if preRx\>ULN, use \>3\*preRx. Blood urea nitrogen (mg/dL)\>2\*preRx. Creatinine (mg/dL)\>1.5\*preRx.
Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality
LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Sodium: \<0.95\*LLN or \>1.05\*ULN or if preRx\<LLN, \<0.95\*preRx or \>ULN, or if preRx\>ULN,\>1.05\*preRx or \<LLN. Potassium,serum: \<0.9\*LLN or \>1.1\*ULN or if preRx\<LLN, use \<0.9\*preRx or \>ULN or if preRx\>ULN, 1.1\*preRx or \<LLN. Phosphorus: 0.75\*LLN or 1.25\*ULN or, if preRx\<LLN, \<0.67\*preRx or \>ULN or, if preRx\>ULN, \<LLN.
Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Number of Participants With Chemistry Laboratory Values Meeting the Criteria for Marked Abnormality
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality: .
Time frame: Day 1 (Baseline) to up to 56 days past the last day of subcutaneous injection in the cumulative study period
Participants With Urinalysis Values Meeting the Criteria for Marked Abnormality
preRX=pretreatment. For all values analyzed (protein, urine; glucose, urine; blood, urine: leukocyte esterase, urine; white blood cells, urine; red blood cells, urine): If missing preRx, use \>=2 or, if value \>= 4, or if preRx=0 or 0.5, use \>=2 or, if preRx= 1, use \>=3 or, if preRx=2 or 3, use \>=4.
Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Number of Participants With Adverse Events of Special Interest
AEs of special interest are AEs that may be associated with the use of immunomodulatory drugs, such as infections, malignancies, autoimmune disorders, and injection reactions (defined as local injection site reactions and systemic injection reactions occurring within 24 hours of subcutaneous injection).
Time frame: Day 1 (Baseline) to up to 56 days past the last day of subcutaneous injection in the cumulative study period
Mean Sitting Systolic and Diastolic Blood Pressure (BP)
BP was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.
Time frame: Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821
Mean Heart Rate
Heart rate was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.
Time frame: Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821
Mean Temperature
Temperature was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.
Time frame: Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821
Mean Trough Serum Concentration (Cmin) of Abatacept
Cmin of abatacept was determined from serum samples.
Time frame: Days 29, 85, 57, and 85
Percentage of Participants With A Positive Anti-abatacept Response (Based on Enzyme-linked Immunosorbent Assay [ELISA]) at Day 85
Using the ELISA, any positive (titer of 400 or greater) postbaseline sample was classified as positive immunogenicity. The percentage of participants with at least 1 positive antibody response (anti-abatacept and/or anti-CTLA4-T) during the 85 days was tabulated by antibody specificity and overall.
Time frame: Day 1 (Baseline) through Day 85
Percentage of Participants With A Positive Anti-abatacept Response (Based on Electrochemiluminescence [ECL] Immunoassay) at Day 85
Number of participants was tabulated using ECL assay with at least 1 positive abatacept-induced immunogenic response (CTLA4 and possibly Ig, Ig and/or Junction Region) in the first 85 days. Positive response (titers \>10) included: * A missing baseline immunogenicity measurement and a positive immunogenicity response postbaseline * A negative baseline immunogenicity response and a positive immunogenicity response postbaseline * A positive baseline immunogenicity response and a positive immunogenicity response postbaseline that has a titer value strictly greater than the baseline titer value
Time frame: Day 1 (Baseline) through Day 85
Mean Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Scores Over Time
The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Time frame: Day 1 (Baseline) through Day 1093
Percentage of Participants With Low Disease Activity Score (LDAS) and Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Remission Over Time:
LDAS is defined as DAS 28-CRP ≤3.2. DAS 28-CRP remission is defined as DAS 28-CRP \<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Time frame: Day 1 (Baseline) through Day 1093
Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time
The HAQ-DI assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories is divided by the number of categories answered, yielding a score from 0-3.
Time frame: Day 1 (Baseline) to Day 1093
Participants were enrolled at 3 locations and 32 sites worldwide: United States (20 sites), Canada (6 sites), and Mexico (6 sites).
| Milestone | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) |
|---|---|---|
| Started | 52 | 71 |
| Completed | 34 | 61 |
| Not completed | 18 | 10 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lack of efficacy | 3 | 3 |
An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators. Systemic injection reaction occurring ≤ 24 hours after dosing.
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Deaths | 0 |
| SAEs | 1 |
| Treatment-related SAEs | 0 |
| SAEs leading to discontinuation | 0 |
| Treatment-related AEs | 11 |
| AEs leading to discontinuation | 1 |
| AEIs: Infections | 20 |
| AEIs: Malignancy | 0 |
| AEIs: Automimmune disorders (prespecified) | 0 |
| AEIs: Injection reactions (prespecified) Local | 2 |
| AEIs: Injection reactions (prespecified) Systemic | 2 |
Cmin of abatacept was determined from serum samples.
| μg/mL | Subcutaneous Abatacept, 125 mg |
|---|---|
| Day 29 (n=116) | 34.31 ± 46 |
| Day 57 (n=117) | 34.25 ± 48 |
| Day 85 (n=118) | 33.78 ± 48 |
An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators.
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Deaths | 4 |
| SAEs | 43 |
| Treatment-related SAEs | 11 |
| SAEs leading to discontinuation | 8 |
| Treatment-related AEs | 60 |
| AEs leading to discontinuation | 11 |
LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Hemoglobin (g/dL) \>3 decrease from preRx. Hematocrit (%)\<0.75\*preRx. Erythrocytes (\*10\^6 c/uL) \<0.75\*preRx. Platelet count (\*10\^9 c/L) \<0.67\*LLN or 1.5\*ULN or, if preRx\<LLN, use \<0.5\*preRx and \<100,000 mm\^3. Leukocytes (\*10\^3 c/uL) \<0.75\*LLN or \>1.25\*ULN or, if preRx\<LLN, use \<0.8\*preRx or \>ULN or, if preRx\>ULN, use \>1.2\*preRx or \<LLN. Eosinophils \>0.750\*10\^3 c/uL. Lymphocytes \<0.750\*10\^3 c/uL or \>7.50\*10\^3 c/uL.
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Hemoglobin, low (n=120) | 7 |
| Hematocrit, low (n=119) | 4 |
| Erythrocytes, low (n=120) | 4 |
| Platelet count, low (n=120) | 2 |
| Leukocytes, low (n=120) | 2 |
| Leukocytes, high (n=120) | 3 |
| Eosinophils (absolute), high (n=122) | 12 |
| Lymphocytes (absolute), low (n=122) | 15 |
LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (U/L) \>2\*ULN or if preRx\>ULN, use 3\*preRx. Alanine aminotransferase (U/L)\>3\*ULN or if preRx\>ULN, use \>4\*preRx. G-glutamyl transferase (U/L)\>2\*ULN or if preRx\>ULN, use \>3\*preRx. Blood urea nitrogen (mg/dL)\>2\*preRx. Creatinine (mg/dL)\>1.5\*preRx.
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Alkaline phosphatase, high (n=120) | 1 |
| Aspartate aminotransferase, high (n=120) | 3 |
| Alanine aminotransferase, high (n=120) | 6 |
| G-glutamyl transferase, high (n=120) | 7 |
| Blood urea nitrogen, high (n=120) | 5 |
| Creatinine, high (n=120) | 11 |
LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Sodium: \<0.95\*LLN or \>1.05\*ULN or if preRx\<LLN, \<0.95\*preRx or \>ULN, or if preRx\>ULN,\>1.05\*preRx or \<LLN. Potassium,serum: \<0.9\*LLN or \>1.1\*ULN or if preRx\<LLN, use \<0.9\*preRx or \>ULN or if preRx\>ULN, 1.1\*preRx or \<LLN. Phosphorus: 0.75\*LLN or 1.25\*ULN or, if preRx\<LLN, \<0.67\*preRx or \>ULN or, if preRx\>ULN, \<LLN.
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Sodium, serum, low (mEq/L) (n=120) | 2 |
| Potassium, serum, low (mEq/L) (n=120) | 6 |
| Phosphorus, inorganic, low (mg/dL) (n=120) | 2 |
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality: .
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Glucose, serum, low (n=122) | 17 |
| Glucose, serum, high (n=122) | 12 |
| Glucose, serum, fasting, low (n=59) | 5 |
| Glucose, serum, fasting, high (n=59) | 3 |
| Protein, total, low (n=120) | 1 |
| Protein, total, high (n=120) | 1 |
| Albumin, low (n=120) | 3 |
Using the ELISA, any positive (titer of 400 or greater) postbaseline sample was classified as positive immunogenicity. The percentage of participants with at least 1 positive antibody response (anti-abatacept and/or anti-CTLA4-T) during the 85 days was tabulated by antibody specificity and overall.
| Percentage of participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Anti-abatacept (n=85) | 8.2 |
| Anti-CTLA4-T9 (n=122) | 0.8 |
Number of participants was tabulated using ECL assay with at least 1 positive abatacept-induced immunogenic response (CTLA4 and possibly Ig, Ig and/or Junction Region) in the first 85 days. Positive response (titers \>10) included: * A missing baseline immunogenicity measurement and a positive immunogenicity response postbaseline * A negative baseline immunogenicity response and a positive immunogenicity response postbaseline * A positive baseline immunogenicity response and a positive immunogenicity response postbaseline that has a titer value strictly greater than the baseline titer value
| Percentage of participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Percentage of Participants With A Positive Anti-abatacept Response (Based on Electrochemiluminescence [ECL] Immunoassay) at Day 85 | 0 |
The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
| Units on a scale | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) |
|---|---|---|
| Day 29 (n=50, 69) | 3.60 ± 1.24 | 2.95 ± 1.31 |
| Day 57 (n=49, 69) | 3.36 ± 1.11 | 2.96 ± 1.37 |
| Day 85 (n=49, 70) | 3.44 ± 1.14 | 2.91 ± 1.30 |
| Day 169 (n=48, 71) | 3.45 ± 1.10 | 2.93 ± 1.29 |
| Day 253 (n=46, 71) | 3.60 ± 1.33 | 3.01 ± 1.21 |
| Day 365 (n=45, 70) | 3.51 ± 1.32 | 3.09 ± 1.25 |
| Day 449 (n=43, 69) | 3.58 ± 1.33 | 3.21 ± 1.35 |
| Day 533 (n=43, 68) | 3.51 ± 1.23 | 3.08 ± 1.43 |
| Day 617 (n=41, 67) | 3.31 ± 1.20 | 3.16 ± 1.37 |
| Day 729 (n=41, 67) | 3.30 ± 1.12 | 3.15 ± 1.26 |
| Day 813 (n=39, 65) | 3.38 ± 1.17 | 2.81 ± 1.05 |
| Day 897 (n=38, 65) | 3.41 ± 1.46 | 3.02 ± 1.19 |
| Day 981 (n=38, 65) | 3.32 ± 1.37 | 3.02 ± 1.28 |
| Day 1093 (n=34, 65) | 3.21 ± 1.26 | 3.10 ± 1.37 |
LDAS is defined as DAS 28-CRP ≤3.2. DAS 28-CRP remission is defined as DAS 28-CRP \<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
| Percentage of participants | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) |
|---|---|---|
| LDAS Day 29 (n=50, 69) | 40.0 (26.4 to 53.6) | 68.1 (57.1 to 79.1) |
| Remission Day 29 (n=50, 69) | 24.0 (12.2 to 35.8) | 50.7 (38.9 to 62.5) |
| LDAS Day 57 (n=49, 69) | 44.9 (31.0 to 58.8) | 60.9 (49.4 to 72.4) |
| Remission Day 57 (n=49, 69) | 26.5 (14.2 to 38.9) | 47.8 (36.0 to 59.6) |
| LDAS Day 85 (n=49, 70) | 40.8 (27.1 to 54.6) | 64.3 (53.1 to 75.5) |
| Remission Day 85 (n=49, 70) | 24.5 (12.4 to 36.5) | 48.6 (36.9 to 60.3) |
| LDAS Day 169 (n=48, 71) | 39.6 (25.7 to 53.4) | 59.2 (47.7 to 70.6) |
| Remission Day 169 (n=48, 71) | 25.0 (12.8 to 37.2) | 49.3 (37.7 to 60.9) |
| LDAS Day 253 (n=46, 71) | 39.1 (25.0 to 53.2) | 66.2 (55.2 to 77.2) |
| Remission Day 253 (n=46, 71) | 30.4 (17.1 to 43.7) | 42.3 (30.8 to 53.7) |
| LDAS Day 365 (n=45, 70) | 40.0 (25.7 to 54.3) | 57.1 (45.5 to 68.7) |
| Remission Day 365 (n=45, 70) | 33.3 (19.6 to 47.1) | 42.9 (31.3 to 54.5) |
| LDAS Day 449 (n=43, 69) | 41.9 (27.1 to 56.6) | 53.6 (41.9 to 65.4) |
| Remission Day 449 (n=43, 69) | 30.2 (16.5 to 44.0) | 43.5 (31.8 to 55.2) |
| LDAS Day 533 (n=43, 68) | 37.2 (22.8 to 51.7) | 60.3 (48.7 to 71.9) |
| Remission Day 533 (n=43, 68) | 23.3 (10.6 to 35.9) | 48.5 (36.7 to 60.4) |
| LDAS Day 617 (n=41, 67) | 46.3 (31.1 to 61.6) | 53.7 (41.8 to 65.7) |
| Remission Day 617 (n=41, 67) | 29.3 (15.3 to 43.2) | 43.3 (31.4 to 55.1) |
| LDAS Day 729 (n=41, 67) | 41.5 (26.4 to 56.5) | 59.7 (48.0 to 71.4) |
| Remission Day 729 (n=41, 67) | 29.3 (15.3 to 43.2) | 34.3 (23.0 to 45.7) |
| LDAS Day 813 (n=39, 65) | 43.6 (28.0 to 59.2) | 69.2 (58.0 to 80.5) |
| Remission Day 813 (n=39, 65) | 25.6 (11.9 to 39.3) | 46.2 (34.0 to 58.3) |
| LDAS Day 897 (n=38, 65) | 50.0 (34.1 to 65.9) | 60.0 (48.1 to 71.9) |
| Remission Day 897 (n=38, 65) | 34.2 (19.1 to 49.3) | 43.1 (31.0 to 55.1) |
| DLAS Day 981 (n=38, 65) | 50.0 (34.1 to 65.9) | 64.6 (53.0 to 76.2) |
| Remission Day 981 (n=38, 65) | 42.1 (26.4 to 57.8) | 46.2 (34.0 to 58.3) |
| LDAS Day 1093 (n=34, 65) | 52.9 (36.2 to 69.7) | 58.5 (46.5 to 70.4) |
| Remission Day 1093 (n=34, 65) | 41.2 (24.6 to 57.7) | 50.8 (38.6 to 62.9) |
The HAQ-DI assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories is divided by the number of categories answered, yielding a score from 0-3.
| Units on a scale | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) |
|---|---|---|
| Day 29 (n=51, 69) | 0.98 ± 0.70 | 0.80 ± 0.67 |
| Day 57 (n=50, 71) | 0.92 ± 0.68 | 0.80 ± 0.67 |
| Day 85 (n=49, 71) | 0.92 ± 0.67 | 0.82 ± 0.69 |
| Day 169 (n=49, 71) | 0.97 ± 0.67 | 0.87 ± 0.74 |
| Day 253 (n=48, 71) | 0.97 ± 0.69 | 0.87 ± 0.73 |
| Day 365 (n=46, 70) | 0.96 ± 0.66 | 0.85 ± 0.69 |
| Day 449 (n=43, 69) | 0.97 ± 0.75 | 0.89 ± 0.69 |
| Day 533 (n=43, 68) | 1.07 ± 0.71 | 0.94 ± 0.71 |
| Day 617 (n=42, 67) | 0.99 ± 0.74 | 0.87 ± 0.69 |
| Day 729 (n=42, 67) | 0.98 ± 0.74 | 0.90 ± 0.71 |
| Day 813 (n=40, 66) | 1.02 ± 0.74 | 0.88 ± 0.68 |
| Day 897 (n=39, 65) | 1.06 ± 0.75 | 0.89 ± 0.73 |
| Day 981 (n=39, 65) | 1.02 ± 0.76 | 0.91 ± 0.69 |
| Day 1093 (n=34, 65) | 0.96 ± 0.74 | 0.92 ± 0.74 |
preRX=pretreatment. For all values analyzed (protein, urine; glucose, urine; blood, urine: leukocyte esterase, urine; white blood cells, urine; red blood cells, urine): If missing preRx, use \>=2 or, if value \>= 4, or if preRx=0 or 0.5, use \>=2 or, if preRx= 1, use \>=3 or, if preRx=2 or 3, use \>=4.
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Protein, urine, high (n=122) | 12 |
| Glucose, urine, high (n=122) | 8 |
| Blood, urine, high (n=122) | 28 |
| Leukocyte esterase, urine, high (n=95) | 32 |
| White blood cells, urine, high (n=103) | 64 |
| Red blood cells, urine, high (n=91) | 33 |
AEs of special interest are AEs that may be associated with the use of immunomodulatory drugs, such as infections, malignancies, autoimmune disorders, and injection reactions (defined as local injection site reactions and systemic injection reactions occurring within 24 hours of subcutaneous injection).
| Participants | Subcutaneous Abatacept, 125 mg |
|---|---|
| Infections | 96 |
| Malignancies | 7 |
| Prespecified autoimmune disorders | 7 |
| Prespecified systemic injection reactions | 14 |
BP was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.
| mm Hg | Subcutaneous Abatacept, 125 mg |
|---|---|
| Sitting Systolic BP Day 1 | 121.6 ± 16.15 |
| Sitting Systolic BP Day 29 (n=120) | 123.6 ± 16.08 |
| Sitting Systolic BP Day 57 (n=120) | 123.9 ± 16.95 |
| Sitting Systolic BP Day 85 (n=120) | 124.3 ± 16.62 |
| Sitting Systolic BP Day 169 (n=116) | 124.0 ± 15.09 |
| Sitting Systolic BP Day 253 (n=114) | 122.3 ± 14.58 |
| Sitting Systolic BP Day 365 (n=114) | 124.1 ± 15.0 |
| Sitting Systolic BP Day 449 (n=111) | 123.9 ± 15.80 |
| Sitting Systolic BP Day 533 (n=108) | 123.5 ± 15.08 |
| Sitting Systolic BP Day 617 (n=109) | 124.4 ± 16.03 |
| Sitting Systolic BP Day 729 (n=108) | 125.2 ± 16.09 |
| Sitting Systolic BP Day 813 (n=105) | 125.6 ± 16.04 |
| Sitting Systolic BP Day 897 (n=102) | 122.8 ± 13.15 |
| Sitting Systolic BP Day 981 (n=101) | 123.5 ± 15.44 |
| Sitting Systolic BP Day 1093 (n=98) | 122.9 ± 13.46 |
| Sitting Systolic BP Day 1177 (n=84) | 124.4 ± 13.66 |
| Sitting Systolic BP Day 1261 (n=73) | 123.0 ± 15.29 |
| Sitting Systolic BP Day 1345 (n=64) | 120.6 ± 12.27 |
| Sitting Systolic BP Day 1457 (n=64) | 124.5 ± 13.17 |
| Sitting Systolic BP Day 1541 (n=64) | 121.0 ± 13.75 |
| Sitting Systolic BP Day 1625 (n=64) | 123.4 ± 14.71 |
| Sitting Systolic BP Day 1709 (n=48) | 122.7 ± 15.55 |
| Sitting Systolic BP Day 1821 (n=3) | 123.7 ± 15.18 |
| Sitting Diastolic BP Day 1 (n=123) | 73.9 ± 8.83 |
| Sitting Diastolic BP Day 29 (n=120) | 75.6 ± 9.28 |
| Sitting Diastolic BP Day 57 (n=120) | 74.3 ± 8.82 |
| Sitting Diastolic BP Day 85 (n=120) | 74.9 ± 10.37 |
| Sitting Diastolic BP Day 169 (n=116) | 74.3 ± 9.19 |
| Sitting Diastolic BP Day 253 (n=114) | 73.9 ± 9.96 |
| Sitting Diastolic BP Day 365 (n=114) | 74.0 ± 9.98 |
| Sitting Diastolic BP Day 449 (n=111) | 74.4 ± 9.53 |
| Sitting Diastolic BP Day 533 (n=108) | 74.8 ± 10.08 |
| Sitting Diastolic BP Day 617 (n=109) | 74.9 ± 9.72 |
| Sitting Diastolic BP Day 79 (n=108) | 75.5 ± 9.83 |
| Sitting Diastolic BP Day 813 (n=105) | 75.8 ± 10.20 |
| Sitting Diastolic BP Day 897 (n=102) | 75.0 ± 10.23 |
| Sitting Diastolic BP Day 981 (n=101) | 75.2 ± 9.35 |
| Sitting Diastolic BP Day 1093 (n=98) | 76.2 ± 10.78 |
| Sitting Diastolic BP Day1177 (n=84) | 77.6 ± 9.04 |
| Sitting Diastolic BP Day 1261 (n=73) | 76.3 ± 9.94 |
| Sitting Diastolic BP Day 1345 (n=64) | 75.4 ± 8.21 |
| Sitting Diastolic BP Day 1457 (n=64) | 76.8 ± 7.14 |
| Sitting Diastolic BP Day 1541 (n=64) | 75.6 ± 9.53 |
| Sitting Diastolic BP Day 1625 (n=64) | 75.6 ± 9.36 |
| Sitting Diastolic BP Day 1709 (n=48) | 75.2 ± 9.74 |
| Sitting Diastolic BP Day 1821 (n=3) | 69.3 ± 8.14 |
Heart rate was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.
| Beats per minute | Subcutaneous Abatacept, 125 mg |
|---|---|
| Day 1 | 74.2 ± 9.56 |
| Day 29 (n=120) | 74.9 ± 8.35 |
| Day 57 (n=120) | 74.6 ± 8.63 |
| Day 85 (n=120) | 74.5 ± 8.90 |
| Day 169 (n=119) | 73.6 ± 9.05 |
| Day 253 (n=115) | 73.9 ± 9.74 |
| Day 365 (n=114) | 73.8 ± 9.37 |
| Day 449 (n=111) | 73.5 ± 9.12 |
| Day 533 (n=109) | 72.7 ± 8.41 |
| Day 617 (n=109) | 73.6 ± 9.83 |
| Day 729 (n=108) | 74.2 ± 9.71 |
| Day 813 (n=105) | 72.8 ± 7.76 |
| Day 897 (n=102) | 72.4 ± 10.05 |
| Day 981 (n=101) | 73.0 ± 8.90 |
| Day 1093 (n=98) | 71.9 ± 9.07 |
| Day 1177 (n=84) | 72.6 ± 8.33 |
| Day 1261 (n=73) | 72.3 ± 9.41 |
| Day 1345 (n=64) | 72.6 ± 8.02 |
| Day 1457 (n=64) | 72.1 ± 7.78 |
| Day 1541 (n=64) | 72.7 ± 8.90 |
| Day 1625 (n=64) | 72.5 ± 8.73 |
| Day 1709 (n=48) | 74.0 ± 9.78 |
| Day 1821 (n=3) | 74.0 ± 6.24 |
Temperature was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.
| Degrees Celsius | Subcutaneous Abatacept, 125 mg |
|---|---|
| Day 1 | 36.4 ± 0.49 |
| Day 29 (n=120) | 36.4 ± 0.43 |
| Day 57 (n=120) | 36.3 ± 0.40 |
| Day 85 (n=120) | 36.4 ± 0.43 |
| Day 169 (n=119) | 36.4 ± 0.41 |
| Day 253 (n=115) | 36.4 ± 0.38 |
| Day 365 (n=114) | 36.3 ± 0.39 |
| Day 449 (n=111) | 36.4 ± 0.46 |
| Day 533 (n=109) | 36.4 ± 0.38 |
| Day 617 (n=109) | 36.4 ± 0.41 |
| Day 729 (n=108) | 36.3 ± 0.33 |
| Day 813 (n=105) | 36.3 ± 0.48 |
| Day 897 (n=102) | 36.4 ± 0.36 |
| Day 981 (n=101) | 36.4 ± 0.44 |
| Day 1093 (n=98) | 36.3 ± 0.43 |
| Day 1177 (n=84) | 36.3 ± 0.39 |
| Day 1261 (n=73) | 36.3 ± 0.41 |
| Day 1345 (n=64) | 36.3 ± 0.33 |
| Day 1457 (n=64) | 36.3 ± 0.39 |
| Day 1541 (n=64) | 36.2 ± 0.36 |
| Day 1625 (n=64) | 36.2 ± 0.43 |
| Day 1709 (n=48) | 36.2 ± 0.37 |
| Day 1821 (n=3) | 36.7 ± 0.21 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subcutaneous Abatacept, 125 mg | — | 43/123 (35%) | 101/123 (82.1%) |
| Event | Subcutaneous Abatacept, 125 mg |
|---|---|
| PneumoniaInfections and infestations | 4/123 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/123 |
| Hiatus herniaGastrointestinal disorders | 2/123 |
| Chest painGeneral disorders | 2/123 |
| Hip fractureInjury, poisoning and procedural complications | 2/123 |
| CholelithiasisHepatobiliary disorders | 2/123 |
| PancytopeniaBlood and lymphatic system disorders | 2/123 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/123 |
| Cerebrovascular accidentNervous system disorders | 1/123 |
| Colonic fistulaGastrointestinal disorders | 1/123 |
| Event | Subcutaneous Abatacept, 125 mg |
|---|---|
| NasopharyngitisInfections and infestations | 34/123 |
| Upper respiratory tract infectionInfections and infestations | 30/123 |
| Urinary tract infectionInfections and infestations | 24/123 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/123 |
| BronchitisInfections and infestations | 14/123 |
| Back painMusculoskeletal and connective tissue disorders | 13/123 |
| HypertensionVascular disorders | 10/123 |
| HeadacheNervous system disorders | 10/123 |
| SinusitisInfections and infestations | 10/123 |
| DizzinessNervous system disorders | 10/123 |
| Age, Continuous(Years) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| Mean | 56.5 ± 10.2 | 52.8 ± 13.8 | 54.3 ± 12.5 |
| Sex: Female, Male(Participants) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| Female | 42 | 59 | 101 |
| Male | 10 | 12 | 22 |
| Race/Ethnicity, Customized(Partcipants) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| White | 47 | 70 | 117 |
| Black/African American | 3 | 0 | 3 |
| American Indian/Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Other | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| North America | 52 | 16 | 68 |
| South America | 0 | 55 | 55 |
| Mean Baseline High Sensitivity C-Reactive Protein Level(μg/mL) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| Mean | 0.94 ± 0.65 | 0.92 ± 0.88 | 0.93 ± 0.79 |
| Mean Baseline 28 Joint Disease Activity Score (DAS 28)(Score on a scale) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| Mean | 3.55 ± 1.20 | 3.28 ± 1.29 | 3.39 ± 1.26 |
| Mean Number of Tender Joints at Baseline(Joints) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| Mean | 9.1 ± 12.8 | 8.8 ± 12.4 | 8.9 ± 12.5 |
| Mean Number of Swollen Joints at Baseline(Joints) | Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure) | Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure) | Total |
|---|---|---|---|
| Mean | 5.4 ± 6.4 | 4.3 ± 5.9 | 4.8 ± 6.1 |
1 further baseline measures are reported on the registry.
The record gives a start of May 2008, a primary completion of Dec 2009 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept